Author/Authors :
Jakobsson, Ulrika Department of Chemistry - University of Helsinki - Helsinki, Finland , Makila, Ermei Department of Physics and Astronomy - University of Turku - Turku, Finland , Airaksinen, Anu J Department of Chemistry - University of Helsinki - Helsinki, Finland , Alanen, Osku Department of Chemistry - University of Helsinki - Helsinki, Finland , Etile, Asenath Department of Chemistry - University of Helsinki - Helsinki, Finland , Koster, Ulli Institut Laue-Langevin - Avenue des Martyrs - Grenoble Cedex, France , Ranjan, Sanjeev Department of Chemistry - University of Helsinki - Helsinki, Finland , Salonen, Jarno Department of Physics and Astronomy - University of Turku - Turku, Finland , Santos, Helder A University of Helsinki - Helsinki, Finland , Helariutta, Kerttuli Department of Chemistry - University of Helsinki - Helsinki, Finland
Abstract :
Mesoporous silicon (PSi) is biocompatible and tailorable material with high potential in drug delivery applications. Here, we
report of an evaluation of PSi as a carrier platform for theranostics by delivering a radioactive ion beam- (RIB-) based radioactive
lanthanoid into tumors in a mouse model of prostate carcinoma. Thermally hydrocarbonized porous silicon (THCPSi) wafers
were implanted with 159Dy at the facility for radioactive ion beams ISOLDE located at CERN, and the resulting [159Dy]THCPSi
was postprocessed into particles. The particles were intratumorally injected into mice bearing prostate cancer xenografts. The
stability of the particles was studied in vivo, followed by ex vivo biodistribution and autoradiographic studies. We showed that the
process of producing radionuclide-implanted PSi particles is feasible and that the [159Dy]THCPSi particles stay stable and local
inside the tumor over seven days. Upon release of 159Dy from the particles, the main site of accumulation is in the skeleton, which
is in agreement with previous studies on the biodistribution of dysprosium. We conclude that THCPSi particles are a suitable
platform together with RIB-based radiolanthanoids for theranostic purposes as they are retained after administration inside the
tumor and the radiolanthanoid remains embedded in the THCPSi.
